News

In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo

The acquisition of Itacel will reinforce Roquette’s position as a major supplier to the pharmaceutical industry and a global leader in natural-based pharmaceutical excipients solutions. The combination of

The Range phase 3 trial evaluated the safety and efficacy of the combination of ramucirumab and docetaxel against placebo and docetaxel in a randomized, double-blinded setting. It featured 531

Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize the following experimental compounds

Adolescents and young adults are a critical demographic for vaccination against MenB due to inherent environmental and social risk factors such as close-quartered living and sharing behaviors. “The

The continued collaboration strengthens the ongoing partnership between the two companies, focusing on the discovery of novel treatments for tropical and neurological diseases at Eisai's 14.5 acre, state-of-the-art

Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA). SAMOS is particularly important as there is currently no validated biomarker in MPS IIIA that reflects CNS

Scientists at Sheffield University’s Institute of Translational Neuroscience (SITraN) believe the drug has demonstrated the potential to prevent the death of motor neurones and stop the onset of the

The CRL does not require Sunovion to conduct any additional clinical studies for the approval of SUN-101/eFlow. Sunovion will work with the FDA to determine an appropriate path